Victor

Researchers are evaluating the effectiveness and safety of Corabotase IPN10200 in adults with moderate to severe glabellar lines, which are wrinkle-like lines between the eyebrows that may affect appearance and confidence. This Phase III study compares a single dose of Corabotase to a placebo in a double-blind phase, followed by an open-label phase to assess repeat doses over time. Participants will receive injections of Corabotase or placebo into selected facial muscles. The study includes a screening period of up to 20 days, a treatment period with up to four treatment cycles where participants may receive Corabotase or placebo in the double-blind phase and Corabotase in the open-label phase, and a follow-up period lasting 24 weeks after the last injection. Multiple visits occur during the first month of treatment, followed by monthly visits. During the study, participants will have health assessments including blood tests, physical exams, ECGs, questionnaires, and diaries. Researchers will measure treatment response at week 4 and monitor safety and satisfaction through week 104. Total participation lasts up to 107 weeks, and participants may withdraw at any time.

Researchers are studying basal cell carcinoma, a type of skin cancer, to evaluate the use of two photon fluorescence microscopy TPFM in detecting residual cancer during standard local excision surgery. The goal is to compare TPFM imaging results with the current standard method of examining surgical margins using permanent tissue sections to confirm if cancer has been fully removed. The study involves imaging excised tissue samples with TPFM to measure the distance from the tumor to the nearest inked surgical margin. After TPFM imaging, the tissue will undergo the usual histological processing with paraffin embedding and slide scanning for margin assessment. Researchers will compare the measurements from the TPFM images to the standard permanent section results to determine how well the new imaging method agrees with conventional pathology. Participants will have their excised tissue imaged with TPFM before it is processed with the standard histology methods. Researchers will collect and analyze data on the agreement between TPFM and permanent sections regarding margin distance and margin status. The primary outcome measure is the quantitative agreement between margin distances measured by TPFM and conventional histology, typically assessed 2 to 4 weeks after surgery. This study does not involve any masking or randomization and will monitor the accuracy of TPFM imaging in this clinical context.

Researchers are evaluating a drug called cemiplimab for treating early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. Cemiplimab helps the immune system attack cancer cells by targeting a protein called PD-1 on immune cells. The studys main goal is to compare how well cemiplimab works when injected directly into the lesion versus standard surgery. Participants will be randomly assigned to receive either cemiplimab injected into the lesion or undergo primary surgery using techniques like Mohs surgery or other complete margin assessment methods. The study will assess side effects and how well cemiplimab performs compared to surgery in treating the cancer. During the study, participants will be monitored for event-free survival up to 3 years. Researchers will also evaluate lesion response, treatment-related adverse events, and sizes of surgical or biopsy defects. The total participation period extends up to 3 years, with regular assessments to track safety and treatment effectiveness.